Arcturus Therapeutics
Company profile
Primary focus
Developing mRNA medicines and vaccines, focused on infectious disease vaccines and rare liver and respiratory diseases.
Why it’s included
The company explicitly develops self-amplifying mRNA vaccines for viral diseases, including pandemic influenza (e.g., 'LUNAR®-H5N1 (ARCT-2304)'), and demonstrates rapid platform adaptation, scalable manufacturing, and formulation technologies directly aligned with the topic.
Relevant capabilities
- Self‑amplifying RNA vaccine development and clinical evaluation
- mRNA design and optimization for vaccines and therapeutics
- Lipid nanoparticle (LNP) formulation and ionizable lipid structure–property design
- Scalable LNP formulation processes and manufacturing technology transfer
- Aerosolized/inhaled LNP formulation and device compatibility testing
Commercial sectorNucleic Acid Vaccine Platforms
Technology classesSelf-amplifying RNA (saRNA) vaccines, Lipid nanoparticle (LNP) delivery systems for RNA vaccines, mRNA vaccines (conventional and nucleoside-modified)
Relevant commercial products
- LUNAR®-FLU (ARCT-2138)
- LUNAR®-H5N1 (ARCT-2304)
- KOSTAIVE®
- Self‑amplifying mRNA COVID‑19 vaccine (clinically evaluated and authorized in select jurisdictions)
- STARR
Relevant patents
2 families, 5 publications- Coronavirus vaccine compositions and methods US-11744887-B2
- Nucleic acid vaccine composition comprising a lipid formulation, and method of increasing the potency of nucleic acid vaccines US-12533410-B2